AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

AbbVie presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making ...

(RTTNews) - AbbVie Inc. (ABBV), Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along with certain interim funding and milestone payments.

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago ...